Granted Patent
B2
US 11,890,349 · App. 17/087,235 · Granted Feb 6, 2024
Treatment of inflammatory diseases with inhibitors of C5A activity
Assignee:
InflaRx GmbH
A61K47/6807A61K31/451A61K31/711A61K39/3955A61P17/00C07K16/18C07K16/2896C07K16/40A61K2039/505C07K2317/24C07K2317/55C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to inhibitors of C5 a activity and their use in the treatment of cutaneous, neutrophilic, inflammatory diseases in a subject.
Claims (3)
1. A method of treating hidradenitis suppurativa (HS) or an HS-related disorder; the method comprising: administering to a subject in need thereof an effective amount of a selective C5a receptor inhibitor, wherein the inhibitor is avacopan having the formula:
wherein the HS-related disorder is selected from Pyoderma gangrenosum (PG); PASH (PG, acne and hidradenitis suppurativa) and PAPASH (pyogenic arthritis, acne, PG and hidradenitis suppurativa).
2. The method of claim 1 , wherein the C5a receptor is C5aR.
Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE THE FIRST ASSIGNOR'S NAME PREVIOUSLY RECORDED AT REEL: 054520 FRAME: 0220. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT.
Recorded Dec 19, 2023
From: GUO, RENFENG; RIEDEMANN, NIELS C.
To: INFLARX GMBH
Reel/Frame 066076/0553 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 2, 2020
From: GUO, RENGFENG; RIEDEMANN, NIELS C.
To: INFLARX GMBH
Reel/Frame 054520/0220 →
Priority Claims (3)
EP 17164573
· Apr 3, 2017
· regional
EP 17177657
· Jun 23, 2017
· regional
EP 17189938
· Sep 7, 2017
· regional
Continuity (3)
Continuation In Part
PCTEP2018050146
· Jan 3, 2018